• Baird et al. Accelerated access to innovative medicines for patients in need. Clin. Pharm Ther. 2014; 96: 559-571
  • Bergmann et al. Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann. Oncology. 2014; 25: 303-306
  • Berntgen et al. Improving the Contribution of Regulatory Assessment Reports to Health Technology Assessments-A Collaboration between the European Medicines Agency and the European network for Health Technology Assessment. Value in Health. 2014 [Epub ahead of print]
  • Cuche M et al. Early dialogue with health technology assessment bodies: a European perspective. IJATC 2014; 30: 571-578
  • Elvidge S. EMA’s parallel advice workshop bridges regulatory and reimbursement divide. Nat. Rev. Drug Discovery. 2014; 13:8
  • Grainger D. Is this the real life? Is this just fantasy? Int. J. Technol. Assess. Health Care. 2014; 30:239-240
  • Husereau et al. Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices. Int. J. Technol. Assess. Health Care. 2014; 30:241-249
  • Klemp M et al. Transcatheter aortic valve implantation and adaptive / progressive coverage. Int. J. Technol. Assess. Health Care. 2014; 30:250-251
  • Schulthess et al. Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law. Chin. Clin. Oncol. 2014; 3:21
  • Trusheim et al. The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions. Health Policy and Technology. 2014; 3:241-247
  • Towse A. Presidents Message: Adaptive pathways to Value Assessment. ISPOR Connections. 2014; 20(5): 3
  • Tarricone R. et al. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play? Expert Review of Pharmacoeconomics & Clinical Research. 2014; 14: 707-718
  • Uguen et al. Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives. Orphanet J Rare Dis. 2014; 9:20
  • Wonder M. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry? Expert Rev Pharmacoecon Outcomes Res. 2014; 14:465-467